Q: What is Xospata used for?

Xospata is used to treat acute myeloid leukemia with FLT3 mutation.

Q: How does Xospata work?

Mechanism of Action Xospata is a type of medication known as a kinase inhibitor. It works by interfering with the activity of specific proteins that contribute to the growth and survival of cancer cells. Targeting FLT3 Mutations In many cases of acute myeloid leukemia (AML), the cancer cells have a mutation in a protein called FLT3 (FMS-like tyrosine kinase 3). This mutation acts like a switch that is stuck in the "on" position, sending continuous signals to the leukemia cells to divide and spread uncontrollably. Xospata is designed to target and block these mutated FLT3 proteins. By binding to these proteins, the medication helps to: Interrupt the signaling pathways that drive rapid cell growth. Slow down or stop the production of abnormal white blood cells. Promote the death of cancer cells that depend on these signals. Because it targets specific proteins found primarily on cancer cells, it is considered a targeted therapy rather than a traditional chemotherapy that affects all rapidly dividing cells in the body.

Q: What are the active ingredients in Xospata?

The active ingredient in Xospata is gilteritinib .

Q: What are the side effects of Xospata?

Common side effects of Xospata may include: Fatigue Diarrhea Nausea Others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Xospata?

Xospata belongs to the FLT3 inhibitor drug class.

Q: What is the dosage of Xospata and how do I take it?

How to Take Xospata Xospata is taken by mouth as a tablet. It is usually taken once a day at the same time every day. You may take this medication with or without food. When taking Xospata, follow these administration guidelines: Swallow the tablets whole. Do not crush, break, or chew the tablets. Missed Doses If you miss a dose, take it as soon as you remember on the same day. If your next scheduled dose is less than 12 hours away, skip the missed dose and take your next dose at the regular time. Do not take two doses at the same time to make up for a missed one. Vomiting If you vomit after taking a dose of Xospata, do not take an extra dose. Simply wait and take your next scheduled dose at the usual time the following day.

Q: Is Xospata safe during pregnancy and breastfeeding?

Pregnancy Xospata can cause harm to an unborn baby. Healthcare providers usually require a pregnancy test before starting this medication to confirm the patient is not pregnant. Effective birth control is necessary during treatment: Females who can become pregnant should use effective contraception during treatment and for at least 6 months after the last dose. Males with female partners who can become pregnant should use effective contraception during treatment and for at least 4 months after the last dose. Breastfeeding It is unknown if this medication passes into breast milk. Due to the risk of serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment and for at least 2 months after the final dose.

Q: What forms and strengths does Xospata come in?

Available Forms Xospata is supplied in the following dosage form: Oral tablet The tablets are film-coated and intended to be swallowed whole. They should not be broken, crushed, or chewed before administration.

Q: What is the FDA approval status of Xospata?

FDA Approval and Indications The U.S. Food and Drug Administration (FDA) approved Xospata in November 2018. It is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation. This mutation must be confirmed by an FDA-approved diagnostic test before treatment begins. Boxed Warning Xospata includes a boxed warning, which is the FDA's most serious warning for medications. This warning concerns differentiation syndrome, a condition that occurs when leukemia cells release chemicals into the blood, potentially leading to inflammation and organ damage. If not recognized and treated early, differentiation syndrome can be fatal. Symptoms may include fever, cough, difficulty breathing, rapid weight gain, or swelling in the arms or legs. Regulatory Requirements and Monitoring Because Xospata is designed to target a specific genetic marker, the FDA approved a companion diagnostic test to identify eligible patients. Regulatory guidance emphasizes the need for healthcare providers to monitor patients for serious side effects, including: Posterior Reversible Encephalopathy Syndrome (PRES): A neurological condition that requires immediate medical attention. Prolonged QT Interval: A heart rhythm condition that can lead to serious arrhythmias. Pancreatitis: Inflammation of the pancreas.

Question 1

What is Xospata?

Accepted Answer

Xospata is a prescription medication that contains the active ingredient gilteritinib. It works by blocking the activity of specific proteins that signal cancer cells to multiply and spread.

By inhibiting these proteins, the medication helps to slow or stop the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors, which are designed to interfere with the biological processes that allow cancer to progress.

Question 2

What is Xospata used for?

Accepted Answer

Xospata is used to treat acute myeloid leukemia with FLT3 mutation.

Question 3

How does Xospata work?

Accepted Answer

Mechanism of Action

Xospata is a type of medication known as a kinase inhibitor. It works by interfering with the activity of specific proteins that contribute to the growth and survival of cancer cells.

Targeting FLT3 Mutations

In many cases of acute myeloid leukemia (AML), the cancer cells have a mutation in a protein called FLT3 (FMS-like tyrosine kinase 3). This mutation acts like a switch that is stuck in the "on" position, sending continuous signals to the leukemia cells to divide and spread uncontrollably. Xospata is designed to target and block these mutated FLT3 proteins.

By binding to these proteins, the medication helps to:

Interrupt the signaling pathways that drive rapid cell growth.
Slow down or stop the production of abnormal white blood cells.
Promote the death of cancer cells that depend on these signals.

Because it targets specific proteins found primarily on cancer cells, it is considered a targeted therapy rather than a traditional chemotherapy that affects all rapidly dividing cells in the body.

Question 4

What are the active ingredients in Xospata?

Accepted Answer

The active ingredient in Xospata is gilteritinib.

Question 5

What are the side effects of Xospata?

Accepted Answer

Common side effects of Xospata may include:

Fatigue
Diarrhea
Nausea
Others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Xospata?

Accepted Answer

Xospata belongs to the FLT3 inhibitor drug class.

Question 7

What is the dosage of Xospata and how do I take it?

Accepted Answer

How to Take Xospata

Xospata is taken by mouth as a tablet. It is usually taken once a day at the same time every day. You may take this medication with or without food.

When taking Xospata, follow these administration guidelines:

Swallow the tablets whole.
Do not crush, break, or chew the tablets.

Missed Doses

If you miss a dose, take it as soon as you remember on the same day. If your next scheduled dose is less than 12 hours away, skip the missed dose and take your next dose at the regular time. Do not take two doses at the same time to make up for a missed one.

Vomiting

If you vomit after taking a dose of Xospata, do not take an extra dose. Simply wait and take your next scheduled dose at the usual time the following day.

Question 8

Is Xospata safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Xospata can cause harm to an unborn baby. Healthcare providers usually require a pregnancy test before starting this medication to confirm the patient is not pregnant.

Effective birth control is necessary during treatment:

Females who can become pregnant should use effective contraception during treatment and for at least 6 months after the last dose.
Males with female partners who can become pregnant should use effective contraception during treatment and for at least 4 months after the last dose.

Breastfeeding

It is unknown if this medication passes into breast milk. Due to the risk of serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment and for at least 2 months after the final dose.

Question 9

What forms and strengths does Xospata come in?

Accepted Answer

Available Forms

Xospata is supplied in the following dosage form:

Oral tablet

The tablets are film-coated and intended to be swallowed whole. They should not be broken, crushed, or chewed before administration.

Question 10

What is the FDA approval status of Xospata?

Accepted Answer

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Xospata in November 2018. It is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation. This mutation must be confirmed by an FDA-approved diagnostic test before treatment begins.

Boxed Warning

Xospata includes a boxed warning, which is the FDA's most serious warning for medications. This warning concerns differentiation syndrome, a condition that occurs when leukemia cells release chemicals into the blood, potentially leading to inflammation and organ damage. If not recognized and treated early, differentiation syndrome can be fatal. Symptoms may include fever, cough, difficulty breathing, rapid weight gain, or swelling in the arms or legs.

Regulatory Requirements and Monitoring

Because Xospata is designed to target a specific genetic marker, the FDA approved a companion diagnostic test to identify eligible patients. Regulatory guidance emphasizes the need for healthcare providers to monitor patients for serious side effects, including:

Posterior Reversible Encephalopathy Syndrome (PRES): A neurological condition that requires immediate medical attention.
Prolonged QT Interval: A heart rhythm condition that can lead to serious arrhythmias.
Pancreatitis: Inflammation of the pancreas.

Question 11

What should I know about Xospata and cost?

Accepted Answer

Cost Factors

Several factors can influence the total cost of Xospata treatment, including:

Insurance Coverage: Your specific health insurance plan, including your deductible, copay, or coinsurance responsibilities.
Prior Authorization: Many insurance companies require a prior authorization process before they will cover this medication.
Specialty Pharmacy: Xospata is typically available only through specialty pharmacies, which may have different pricing structures than retail pharmacies.

Generic Status

Xospata is a brand-name medication containing the active ingredient gilteritinib. Currently, there is no generic version available. Brand-name drugs are generally more expensive than generics because they are protected by patents that prevent other companies from making the same drug for a certain period.

Financial Assistance Programs

The manufacturer of Xospata may offer financial assistance programs to help eligible patients manage the cost. These can include copay cards for those with commercial insurance or patient assistance programs for those who are uninsured or underinsured. Patients are encouraged to discuss these options with their healthcare team or a specialty pharmacist.

Xospata

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Xospata

Hospitals.net Disclosure